Evidence map›Paper›PMID 38038687›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough.

Varintra E Lander, David G DeNardo

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Varintra E LanderDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-8299-7104
David G DeNardoDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-3655-5783

Funding

Washington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI Ryan C Fields · 2023 to 2026
$10.7M
Washington University (WU) ROBIN Center: MicroEnvironment and Tumor Effects Of Radiotherapy (METEOR)U54CA274318 · NCI · WASHINGTON UNIVERSITY · PI Clifford Grant Robinson, Julie Kristina Schwarz · 2023 to 2026
$7.7M
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic CancerR01CA177670 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G · 2014 to 2023
$3.3M
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast CancerR01CA262555 · NCI · WASHINGTON UNIVERSITY · PI AFT, REBECCA L., DENARDO, DAVID G · 2021 to 2025
$3.2M
Re-wiring PDAC Tumor Immunity Through Dendritic CellsR01CA262506 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, DESELM, CARL · 2021 to 2025
$2.8M
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor ImmunityR01CA248917 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, KIM, HYUN · 2020 to 2024
$2.5M
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor ImmunityU01CA284086 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, Li Ding · 2023 to 2026
$2.3M
Exploiting Integrin Signaling to Overcome Resistance to ImmunotherapyR01CA244938 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, GUPTA, VINEET · 2020 to 2024
$2.2M
Elucidating the protective role of stromal fibrosis to radiation-induced tumor immunityF30CA243233 · NCI · WASHINGTON UNIVERSITY · PI LANDER, VARINTRA EDLYN · 2019 to 2022
$165k
NCI NIH HHS F30 CA243233NCI NIH HHS P50 CA272213NCI NIH HHS R01 CA177670NCI NIH HHS R01 CA244938NCI NIH HHS R01 CA248917NCI NIH HHS R01 CA262506NCI NIH HHS R01 CA262555NCI NIH HHS U01 CA284086NCI NIH HHS U54 CA274318
6 · The paper itself

Abstract

PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFκB signaling, which may limit productive tumor-controlling immunity. See related article by Ali et al., p. 542.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCD8-Positive T-LymphocytesHumansPancreasT-Lymphocytes

Identifiers

PMID38038687
PMCPMC10842790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.